Ctni-36. The Feasibility Of Using Bortezomib With Chemotherapy In Atypical Teratoid/Rhabdoid Tumors
Wan-Ling Ho,Ming-Yun Hsieh,Yu-Mei Liao,Shyh-Shin Chiou,Her-Shyong Shiah,Chang-Hsu Chiang,Shiann-Tarng Jou,Hsu-Ju Yen,Yi-Yen Lee,Muh-Lii Liang,Ting-Chi Yeh,Yu-Cheng Chou,Fang-Liang Huang,Shu-Huey Chen,Hsin-Lun Lee,Chia-Chun Kuo,Shu-Mei Chen,Min-Lan Tsai,Hsi Chang,Kevin Li-Chun Hsieh,Chia-Lang Fang,Chia-Yau Chang,Jinn-Li Wang,Chu-Chin Chen,Joon-Khim Loh,Pei-Chin Lin,Tzu-Chin Lin,Shih-Chung Wang,Yi-Fang Tu,Chao-Neng Cheng,Ming-Jung Chuang,Huy Minh Tran,Shian-Ying Sung,Irving Lai,Kuo-Sheng Wu,James S Miser,Yen-Lin Liu,Tai-Tong Wong
DOI: https://doi.org/10.1093/neuonc/noae165.0403
2024-11-29
Neuro-Oncology
Abstract:Atypical teratoid/rhabdoid tumors (ATRTs) are highly aggressive pediatric brain tumors with sensitivity to proteasome inhibitors in preclinical models. We evaluated the feasibility of combining the proteasome inhibitor bortezomib with chemotherapy. Patients aged 0-20 years with newly diagnosed ATRT were enrolled from January 2022 through December 2023. A modified Medical University of Vienna (MUV)-ATRT regimen was used. They were treated with bortezomib of 1.3 mg/m 2 /dose given intravenously or subcutaneously twice a week for 2 weeks concurrently with 6 cycles of chemotherapy and 2 additional cycles after high-dose chemotherapy. Radiation therapy was given prior to or at the end of chemotherapy. A total of 36 chemotherapy cycles with bortezomib in 6 patients were evaluated. The primary endpoint was grade 3 or higher non-hematologic toxicities. Numbers of cycles with grade 3+ toxicities included: AST/ALT elevation (1), hypokalemia (2), peripheral neuropathy (1), subdural hemorrhage (2), vomiting (2), oral mucositis (3), lung infection (2), urinary tract infection (8), sepsis (3), febrile neutropenia (20). No grade 3+ toxicities were considered bortezomib-related. Three patients completed 8 cycles of bortezomib treatment; 2 patients discontinued the study due to progressive disease after 2 and 4 cycles respectively; 1 patient completed 6 cycles of bortezomib and died of septic shock in complete remission after high-dose chemotherapy. Two patients had a surgical complete resection. Three patients were evaluable for response after bortezomib: 1 partial response and 2 stable disease. Two patients had progression-free survival for 16 + and 22 + months after diagnosis, respectively. Among the 3 patients with progressive disease , 2 had metastatic relapse and 1 had primary and metastatic relapse. There were 4 deaths due to metastatic PD ( n =2), septic shock after high-dose chemotherapy ( n =1), and septic shock after 2nd line treatment for PD ( n =1). We conclude that adding bortezomib to standard and high-dose chemotherapy of ATRT was feasible with the occurrence of grade 3/4 toxicities no more than what was expected with chemotherapy alone. Metastatic relapse remains the major challenge of ATRT treatment.
oncology,clinical neurology